This report is an open-label case series of seven depressed adolescents with bipolar disorder treated with uridine for 6 weeks. Treatment response was measured with the Children's Depression Rating Scale-Revised and the Clinical Global Impressions scale. Uridine was associated with decreased depressive symptoms, and was well tolerated by study participants. Further systematic studies of uridine are warranted.
Get full access to this article
View all access options for this article.
References
1.
AndreazzaAC, ShaoL, WangJF, YoungLT. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry, 67:360–368. 2010.
2.
BecroftDM, PhillipsLI, SimmondsA. Hereditary orotic aciduria: Long-term therapy with uridine and a trial of uracil. J Pediatr, 75:885–891. 1969.
3.
CansevM. Uridine and cytidine in the brain: Their transport and utilization. Brain Res Rev, 52:389–397. 2006.
4.
CarlezonWAJr., MagueSD, ParowAM, StollAL, CohenBM, RenshawPF. Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in rats. Biol Psychiatry, 57:343–350. 2005.
5.
CarlezonWA, PliakasAM, ParowAM, DetkeMJ, CohenBM, RenshawPF. Antidepressant-like effects of cytidine in the forced swim test in rats. Biol Psychiatry, 51:882–889. 2002.
6.
ColettiDJ, LeighE, GallelliKA, KafantarisV. Patterns of adherence to treatment in adolescents with bipolar disorder. J Child Adolesc Psychopharmacol, 15:913–917. 2005.
7.
DagerSR, FriedmanSD, ParowA, DemopulosC, StollAL, LyooIK, DunnerDL, RenshawPF. Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry, 61:450–458. 2004.
8.
DelBelloMP, HansemanD, AdlerCM, FleckDE, StrakowskiSM. Twelve-month outcome of adolescents with bipolar disorder following first hospitalization for a manic or mixed episode. Am J Psychiatry, 164:582–590. 2007.
9.
DrotarD, GreenleyRN, DemeterCA, McNamaraNK, StansbreyRJ, CalabreseJR, StangeJ, VijayP, FindlingRL. Adherence to pharmacological treatment for juvenile bipolar disorder. J Am Acad Child Adolesc Psychiatry, 46:831–839. 2007.
10.
FrazierEA, FristadMA, ArnoldLE. Multinutrient supplement as treatment: Literature review and case report of a 12-year-old boy with bipolar disorder. J Child Adolesc Psychopharmacol, 19:453–460. 2009.
KatoT. Mitochondrial dysfunction as the molecular basis of bipolar disorder: Therapeutic implications. CNS Drugs, 21:1–11. 2007.
13.
KatoT. The role of mitochondrial dysfunction in bipolar disorder. Drug News Perspect, 19:597–602. 2006.
14.
KaufmanJ, BirmaherB, BrentD, RaoU, FlynnC, MoreciP, WilliamsonD, RyanN. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry, 36:980–988. 1997.
15.
KonradiC, EatonM, MacDonaldML, WalshJ, BenesFM, HeckersS. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry, 61:300–308. 2004.
16.
KowatchRA, FristadM, BirmaherB, WagnerKD, FindlingRL, HellanderM. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry, 44:213–235. 2005.
17.
LehningerA, NelsonDM, CoxMM. Lehninger Principles of Biochemistry, fifth. New York: W.H. Freeman, 2008.
18.
MartinetM, FonluptP, PachecoH. Effects of cytidine-5′ diphosphocholine on norepinephrine, dopamine and serotonin synthesis in various regions of the rat brain. Arch Int Pharmacodyn Ther, 239:52–61. 1979.
19.
MartinetM, FonluptP, PachecoH. Interaction of CDP-choline with synaptosomal transport of biogenic amines and their precursors in vitro and in vivo in the rat corpus striatum. Experientia, 34:1197–1199. 1978.
20.
McClellanJ, KowatchR, FindlingRL. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry, 46:107–125. 2007.
21.
PavuluriMN, HenryDB, DevineniB, CarbrayJA, NaylorMW, JanicakPG. A pharmacotherapy algorithm for stabilization and maintenance of pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry, 43:859–867. 2004.
22.
PoggeDL, SingerMB, HarveyPD. Rates and predictors of adherence with atypical antipsychotic medication: A follow-up study of adolescent inpatients. J Child Adolesc Psychopharmacol, 15:901–912. 2005.
23.
PosnerK. Columbia-Suicide Severity Rating Scale (C-SSRS)New York: Center for Suicide Risk Assessment, Columbia University Medical Center, 2010.
24.
PoznanskiEO, MokrosHB. Children's Depression Rating Scale, Revised (CDRS-R) Manual. Los Angeles, CA: Western Psychological Services, 1996.
25.
QuirozJA, GrayNA, KatoT, ManjiHK. Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology, 33:2551–2565. 2008.
26.
RegenoldWT, PhatakP, MaranoCM, SassanA, ConleyRR, KlingMA. Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: Implications for the mitochondrial dysfunction hypothesis. Biol Psychiatry, 65:489–494. 2009.
27.
Repligen: Phase II study to assess RG2417 in the treatment of bipolar I depression. ClinicalTrials.gov[Internet]Bethesda, MD: U.S. National Library of Medicine, 2006.
28.
Repligen: A study to assess the safety, tolerability, efficacy of RG2717 in bipolar I depression. ClinicalTrials.gov[Internet]Bethesda, MD: U.S. National Library of Medicine, 2008.
29.
SanacoraG, ZarateCA, KrystalJH, ManjiHK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov, 7:426–437. 2008.
30.
StorkC, RenshawPF. Mitochondrial dysfunction in bipolar disorder: Evidence from magnetic resonance spectroscopy research. Mol Psychiatry, 10:900–919. 2005.
31.
SugawaraM, SatoN, NakanoT, IdotaT, NakajimaI. Profile of nucleotides and nucleosides of human milk. J Nutr Sci Vitaminol (Tokyo), 41:409–418. 1995.
32.
ThorellL, SjobergLB, HernellO. Nucleotides in human milk: Sources and metabolism by the newborn infant. Pediatr Res, 40:845–852. 1996.
33.
United States Food and Drug Administration. Guidance for Industry. E6 Good Clinical Practice: Consolidated Guidance. Rockville, MD, 1996; 7.
WebsterDR. Hereditary orotic aciduria, other disorders of pyrimidine metabolism. The Metabolic and Molecular Bases of Inherited Disease. ScriverC.R., BeaudetA.L., SlyW.S., ValleD.New York: McGraw-Hill Professional, 1995.
36.
WurtmanRJ. Synapse formation and cognitive brain development: Effect of docosahexaenoic acid and other dietary constituents. Metabolism 57 Suppl, 2:S6–S10. 2008.
37.
WurtmanRJ, CansevM, UlusIH. Synapse formation is enhanced by oral administration of uridine and DHA, the circulating precursors of brain phosphatides. J Nutr Health Aging, 13:189–197. 2009.
38.
WurtmanRJ, ReganM, UlusI, YuL. Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol, 60:989–992. 2000.
39.
YoonSJ, LyooIK, HawsC, KimTS, CohenBM, RenshawPF. Decreased glutamate/glutamine levels may mediate cytidine's efficacy in treating bipolar depression: A longitudinal proton magnetic resonance spectroscopy study. Neuropsychopharmacology, 34:1810–1818. 2009.
40.
YoungRC, BiggsJT, ZieglerVE, MeyerDA. A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry, 133:429–435. 1978.
